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Synthesis of SiR-PyPDS analogues 
 
All solvents and reagents were purified by standard techniques reported in Armarego, 
W.L.F., Chai, C.L.L., Purification of Laboratory Chemicals, 5th edition, Elsevier, 2003; 
or used as supplied from commercial sources (Sigma-Aldrich Corporation® unless 
stated otherwise). NMR spectra were acquired on Bruker® DRX-400, Bruker® DPX-
400 and DRX-500 instruments using deuterated solvents as detailed and at ambient 
probe temperature (300 K). Chemical shifts (δ) are given in ppm and coupling 
constants in Hz. 1H and 13C NMR spectra are referenced to the deuteriated solvent 
residual peaks, namely CDCl3 (7.260 ppm; 77.16 ppm), CD3OD (3.310 ppm and 4.780 
ppm; 49.15 ppm). Notation for the 1H-NMR spectral splitting patterns includes: singlet 
(s), doublet (d), triplet (t), broad (br) and multiplet/overlapping peaks (m). Signals are 
quoted as δ values in ppm, coupling constants (J), are quoted in Hertz and 
approximated to the nearest 0.5. For the assignments of the 1H and 13C NMR DQF- 
COSY, HSQC and HMBC experiments were also performed. Data analysis for the 
nuclear magnetic resonance (NMR) spectra was performed using MestReNova® 
software, version 11.0.4. Mass spectra were recorded on a Micromass® Q-Tof (ESI) 
spectrometer. Thin layer chromatography (TLC) was performed on Merck Kieselgel 
60 F254 plates, and spots were visualized under UV light. Flash chromatography (FC) 
was performed using Merck Kieselgel 60 at rt under a positive pressure of nitrogen 
using previously distilled solvents. High performance liquid chromatography (HPLC) 
purification was carried out on all final compounds by using a Varian Pursuit C18, 5 μ 
column (250 × 21.2 mm) and a gradient elution with H2O/MeCN containing 0.1% TFA 
at a flow rate of 12.0 mL/min. Values were recorded on a Perkin Elmer® 241 
polarimeter. All final compounds had a purity of ≥95% as assessed by LCMS.  
 
Synthesis of Py-PDS, as reported in supporting reference 1. 
Unlike PDS, pyrrolidine-based side chains on the quinoline rings of the scaffold were 
employed in the synthesis of SiR-PyPDS and SiR-iPyPDS. This chemical modification 
ensured chemo-selective SiR-labelling of the central pyridine over the two quinolines 
of the scaffold.  
 
(i) Chelidamic acid dimethyl ester. Chelidamic acid hydrate (10.0 g, 50.8 mmol) was 
dissolved in 100 ml SOCl2 and refluxed overnight. The solvent was removed in vacuo 
and a yellow solid was obtained, which was quenched with 100 mL of freshly distilled 
MeOH at 0 °C. The excess solvent was then removed in vacuo. The crude product 
was dissolved in 200 mL of a sat. aq. NaHCO3 solution and washed with 100 mL 
EtOAc. The aqueous layer was then recovered, acidified with conc. HCl to pH 4 and 
extracted with EtOAc. The organic layer was dried over MgSO4, filtered, and the 
solvent removed in vacuo to obtain the product as a white powder (3.4 g, 16.1 mmol, 
29%). 1H-NMR (400 MHz, CDCl3) δH 7.39 (2H, br s), 3.92 (6H, s). The spectroscopic 
data were in agreement with the literature (2).  
 
(ii) 4-(2-((tert-butoxycarbonyl)amino)ethoxy)pyridine-2,6-dicarboxylate (1a). 
Chelidamic acid dimethyl ester (1.5 g, 7.1 mmol), N-Boc-ethanolamine (1.7 g, 10.5 
mmol) and triphenylphosphine (3.7 g, 14.1 mmol) were dissolved in 50 mL freshly 
distilled THF and cooled to 0 °C. DIAD (1.9 mL, 9.9 mmol) was added dropwise under 
argon. The mixture was allowed to warm to rt and stirred for 3 d. The solvent was 
removed in vacuo and the product purified by column chromatography (50% EtOAc, 
50% petroleum ether) to obtain the dimethyl ester of the title compound as a white 
powder. This compound was dissolved in 50 mL MeOH and deprotected by slowly 
adding a solution of NaOH (0.4 g, 10.6 mmol) in 50 mL H2O. The solvent was 
evaporated in vacuo and the remaining solid dissolved in H2O. The solution was 
acidified with 5% HCOOH(aq.) and extracted with EtOAc. The organic layer was dried 
over MgSO4, filtered, and the solvent removed in vacuo to obtain the title compound 
as a white powder (1.5 g, 4.6 mmol, 64%). 1H NMR (500 MHz, CD3OD) δH 7.86 (2H, 
s), 4.26 (2H, t, J 5.0 Hz), 3.49 (2H, t, J 5.0 Hz), 1.42 (9H, s); 13C-NMR (125 MHz, 
CD3OD) δC 169.4, 167.0, 158.4, 150.3, 115.2, 80.5, 69.6, 40.7, 28.6; HRMS (ES) 
calculated for C14H17N2O7 ([M+H]+) m/z: 325.1041, found 325.1046. The 
spectroscopic data were in agreement with the literature (2).  
 
(iii) 4-(2-(pyrrolidin-1-yl)ethoxy)quinolin-2-amine (2a). 2-Amino-quinolinone (0.68 
g, 4.2 mmol), N-(2-hydroxyethyl)-pyrrolidine (1.2 mL, 10.6 mmol, 2.5 equiv.) and 
triphenylphosphine (2.8 g, 10.6 mmol) were dissolved in 100 mL of freshly distilled 
THF and cooled to 0 °C. DIAD (2.1 mL g, 10.6 mmol) was added dropwise under 
argon. The mixture was allowed to warm to rt and stirred for 4 d. The reaction was 
worked up by extracting three times with HCl(aq) 0.1M, then the aqueous fraction was 
neutralized with NaOH(aq) and extracted again with DCM. The solvent was removed in 
vacuo and the product purified by column chromatography (89.5% EtOAc, 10% 
MeOH, 0.5% TEA) and left for 3 d under high vacuum to remove residues of alcohol 
and to obtain the title compound as a white powder (219 mg, 0.9 mmol, 21%). 1H-NMR 
(400 MHz, CD3OD) δH 8.00 (1H, dd, J 8.0, 1.0 Hz), 7.53 (1H, dd, J 8.0, 1.5 Hz), 7.48 
(1H, ddd, J 8.0, 6.5, 1.0 Hz), 7.20 (1H, ddd, J 8.0, 6.5, 1.5 Hz), 6.28 (1H, s), 4.33 (2H, 
t, J 5.5 Hz), 3.10 (2H, t, J 5.5 Hz), 2.81-2.73 (4H, m), 1.94-1.82 (4H, m); 13C-NMR (100 
MHz, CD3OD) δC 163.0, 160.3, 148.0, 130.2, 124.1, 121.9, 121.6 , 110.8, 90.4, 67.6, 
54.8, 54.6, 23.3; HRMS (ES) calculated for C15H20N3O ([M+H]+) m/z: 258.1606, found 
258.1611. The spectroscopic data were in agreement with the literature (2).  
 
(iv) 4-(2-aminoethoxy)-N2,N6-bis(4-(2-(pyrrolidin-1-yl)ethoxy)quinolin-2-
yl)pyridine- 2,6-dicarboxamide (Py-PDS). The pyridine dicarboxylate 1a (56 mg, 
0.17 mmol) was dissolved in DCM (≈ 0.5 M) at 0 °C and 1-chloro-N,N,2-
trimethylpropenylamine (47.6 μL, 0.36 mmol, 2.2 equiv.) was slowly added. The 
reaction was allowed to stir at rt for 1.5 h checking the completion by LC-MS. The 
solution was then cooled to 0 °C and triethylamine (50.2 μL, 0.36 mmol, 2.2 equiv.) 
was carefully added dropwise. The reaction was then allowed to warm to rt and it was 
kept stirring for another 1 h. The quinoline 2a (92 mg, 0.36 mmol, 2.2equiv.) was added 
to the mixture as a DCM solution (≈ 1.0 M) and stirred at rt overnight. The intermediate 
was nearly purified by flash column (94.5% DCM, 5% MeOH, 0.5% TEA) to obtain a 
crude that was treated overnight with a 1:10 mixture of TFA in DCM. The final 
compound was purified using HPLC (gradient: 10% MeCN/90% H2O, 0.1% TFA to 
100% MeCN, 0.1% TFA over 30 min, Rt=12.0-13.5 min) to afford the TFA salt of the 
title compound as a white powder (Py-PDS×3CF3CO2H, 27.8 mg, 0.027 mmol, 16%). 
1H-NMR (400 MHz, CD3OD) δH 8.48 (2H, br d, J 8.0 Hz), 8.21 (2H, s), 8.17 (2H, s), 
8.12 (2H, br d, J 8.0 Hz), 8.01 (2H, ddd. J 8.0, 6.5, 1.0 Hz), 7.75 (2H, ddd, J 8.0, 6.5, 
1.0 Hz), 4.98-4.93 (4H, m), 4.69-4.63 (2H, m), 4.07-3.99 (4H, m), 3.97-3.85 (4H, m), 
3.61-3.53 (2H, m), 3.48-3.34 (4H, m), 2.36-2.08 (8H, m); 13C-NMR (100 MHz, CD3OD) 
δC 168.2, 167.2, 163.7, 151.0, 149.7 139.5, 134.4, 127.6, 123.5, 121.3, 118.8, 113.9, 
94.7, 66.4, 65.7, 55.2, 53.6, 39.1, 23.1; HRMS (ES) calculated for C39H45N8O5 
([M+H]+) m/z: 705.3501, found 705.3510. The spectroscopic data were in agreement 
with the literature (1).  
 




(iii) 8-(2-(pyrrolidin-1-yl)ethoxy)quinolin-2-amine (2b). 2-Amino-8-quinolinol (2.1 g, 





























triphenylphosphine (8.5 g, 32 mmol) were dissolved in 100 mL of freshly distilled THF 
and cooled to 0 °C. DIAD (6.4 mL, 32 mmol) was then added dropwise under argon. 
The mixture was allowed to warm to rt and stirred for 4 d. The reaction was worked up 
by extracting three times with 0.1 M HCl(aq), then the aqueous fraction was neutralized 
with NaOH(aq) and extracted again with DCM. The solvent was removed in vacuo and 
the product purified by column chromatography (89.5% DCM, 10% MeOH, 0.5% TEA) 
and left for 1 d under high vacum to remove residues of alcohol and to obtain the title 
compound as a white powder (1.45 g, 5.7 mmol, 44%). 1H-NMR (400 MHz, CDCl3) δ 
7.73 (d, J = 8.9 Hz, 1H), 7.15 (d, J = 7.3 Hz, 1H), 7.06 (t, J = 7.9 Hz, 1H), 6.92 (d, J = 
7.3 Hz, 1H), 6.68 (d, J = 8.9 Hz, 1H), 4.28 (t, J = 5.5 Hz, 2H), 3.12 (t, J = 5.4 Hz, 2H), 
2.82 – 2.74 (m, 4H), 1.93 – 1.85 (m, 4H); 13C-NMR (101 MHz, CDCl3) δ 158.0, 152.1, 
137.9, 137.9, 123.9, 121.4, 120.1, 112.9, 109.8, 66.5, 55.0, 54.1, 23.6; HRMS (ES) 
calculated for C15H20N3O ([M+H]+) m/z: 258.1601, found 258.1594.  
 
(iv) 4-(2-aminoethoxy)-N2,N6-bis(8-(2-(pyrrolidin-1-yl)ethoxy)quinolin-2-
yl)pyridine-2,6-dicarboxamide (iPyPDS). The pyridine dicarboxylate 1b (50 mg, 0.15 
mmol) was dissolved in DCM (≈ 0.5 M) at 0 °C and 1-chloro-N,N,2-
trimethylpropenylamine (42.3 μL, 0.32 mmol, 2.2equiv.) was added slowly. The 
reaction was allowed to stir at rt for 1.5 h checking the completion by LC-MS. The 
solution was then cooled to 0 °C again and triethylamine (44.6 μL, 0.32 mmol, 
2.2equiv.) was carefully added dropwise inside the solution and it was allowed to warm 
to rt and stirred for another 1 h. The quinoline 2b (82 mg, 0.32 mmol, 2.2equiv.) was 
added to the mixture as DCM solution (≈ 1.0 M) and stirred at rt overnight. The 
intermediate was nearly purified by flash column (79.5% DCM, 20% MeOH, 0.5% 
TEA) to obtain a crude that was treated overnight with a 1:10 mixture of TFA in DCM. 
The final compound was purified using HPLC (gradient: 10% MeCN/90% H2O, 0.1% 
TFA to 100% MeCN, 0.1% TFA over 30 min, Rt=12.0-13.5 min) to afford the TFA salt 
of the title compound as a white powder (iPyPDS×3CF3CO2H, 18.9 mg, 0.018 mmol, 
12%). 1H-NMR (500 MHz, CD3OD) δ 8.58 (d, J = 8.9 Hz, 2H), 8.43 (d, J = 9.0 Hz, 2H), 
8.17 (s, 2H), 7.67 (d, J = 8.2 Hz, 2H), 7.59 (t, J = 8.0 Hz, 2H), 7.40 (d, J = 7.3 Hz, 2H), 
4.62 – 4.57 (m, 6H), 3.70 – 3.62 (m, 4H), 3.57 – 3.49 (m, 4H), 3.31 – 3.28 (m, 4H), 
3.09 – 2.09 (m, 2H), 1.93 – 1.73 (m, 8H); 13C-NMR (126 MHz, CD3OD) δ 168.9, 163.9, 
162.5, 162.2, 152.7, 151.8, 151.1, 141.7, 141.5, 128.9, 127.7, 122.2, 117.3, 113.6, 
112.8, 66.6, 65.2, 55.1, 54.8, 39.7, 23.6; HRMS (ES) calculated for C39H45N8O5 











CONJUGATION with SiR-Cn 
In a typical reaction, 30-50 equivalents of DIEA and 1.1 equivalents of a 100 mM 
solution of TSTU in DMSO are added to a DMSO solution of SiR-Cn-COOH 
(Spirochrome ®) 1 equivalent. The colourless mixture is kept at rt for 5 min under 
shaking followed by addition of a solution of PDS analogue (1.1 equivalents of a 50 
mM DMSO solution). The mixture is kept shaking for 4-18 hours until completion, as 
assessed by LC-MS. Afterwards, a double volume of milliQ water is added to the 
mixture and directly injected on HPLC (gradient: 10% MeCN/90% H2O, 0.1% TFA to 
100% MeCN, 0.1% TFA over 30 min, Rt=11.0-14.5 min). The collected peaks are dried 




SiR-C6-COOH (183 μL, 13.5 mM, 1.1 equiv.), DIEA (10 μL, 30 eq), TSTU (25 μL, 100 
mM, 1.1 eq) and Py-PDS (45 μL, 50 mM, 1 eq) were left react together for 12 hours 
following the general method above. The final compound was dried to afford the TFA 
salt of the title compound as an intense blue powder (SiR-C6-PyPDS×2CF3CO2H, 1.94 
mg, 1.29 μmol, 58%). 1H-NMR (500 MHz, CD3OD) δ 8.40 (dd, J = 8.3, 0.8 Hz, 2H), 
8.20 (s, 2H), 8.15 (d, J = 8.2 Hz, 1H), 8.06 (s, 2H), 8.05 – 8.00 (m, 3H), 7.90 (td, J = 
8.4, 7.0, 1.4 Hz, 2H), 7.82 (d, J = 1.4 Hz, 1H), 7.66 (td, J = 8.1, 6.9, 1.1 Hz, 2H), 7.18 
(d, J = 2.8 Hz, 2H), 6.89 (d, J = 9.4 Hz, 2H), 6.66 (dd, J = 9.4, 2.9 Hz, 2H), 4.83 (t, J = 
4.6 Hz, 4H), 4.31 (t, J = 5.5 Hz, 2H), 3.97 (t, J = 4.6 Hz, 4H), 3.64 (t, J = 5.3 Hz, 2H), 
3.37 (t, J = 6.9 Hz, 2H), 3.16 (s, 12H), 2.27 (t, J = 7.1 Hz, 2H), 2.19 (s, 8H), 1.75 – 
1.66 (m, 2H), 1.66 – 1.59 (m, 2H), 1.46 – 1.36 (m, 2H), 0.68 (s, 3H), 0.52 (s, 3H). 13C-
NMR (126 MHz, CD3OD) δ 176.5, 169.7, 168.2, 165.1, 164.0, 162.3, 162.0, 152.8, 
151.5, 146.1, 139.7, 133.2, 130.3, 128.8, 127.1, 126.4, 123.5, 120.5, 120.4, 114.9, 
113.8, 95.7, 68.9, 66.1, 56.2, 54.8, 41.0, 40.8, 39.4, 36.7, 31.7, 30.0, 29.1, 27.4, 26.4, 
24.0, 22.4, 13.3, -0.3, -1.9. HRMS (ES) calculated for C72H82N11O9Si+ ([M+H]2+) m/z: 
636.8067, found 636.8047.  



























SiR-C6-COOH (183 μL, 13.5 mM, 1.1 equiv.), DIEA (10 μL, 30 eq), TSTU (25 μL, 100 
mM, 1.1 eq) and iPyPDS (45 μL, 50 mM, 1 eq) were left react together for 12 hours 
following the general method above. The final compound was dried to afford the TFA 
salt of the title compound as an intense blue powder (SiR-C6-iPyPDS×2CF3CO2H, 0.76 
mg, 0.51 μmol, 23%). 1H-NMR (500 MHz, CD3OD) δ 8.55 (d, J = 9.0 Hz, 2H), 8.43 (d, 
J = 8.9 Hz, 2H), 8.20 (d, J = 8.2 Hz, 1H), 8.10 (s, 2H), 8.06 (dd, J = 8.2, 1.7 Hz, 1H), 
7.75 (d, J = 1.8 Hz, 1H), 7.68 (dd, J = 8.3, 1.1 Hz, 2H), 7.60 (t, J = 8.0 Hz, 2H), 7.39 
(dd, J = 7.9, 1.2 Hz, 2H), 7.29 (d, J = 2.9 Hz, 2H), 6.94 (d, J = 9.5 Hz, 2H), 6.73 (dd, J 
= 9.5, 2.8 Hz, 2H), 4.57 (t, J = 5.0 Hz, 4H), 4.38 (t, J = 5.4 Hz, 2H), 3.66 (dt, J = 5.4, 
4.9 Hz, 6H), 3.38 (t, J = 7.2 Hz, 2H), 3.26 (s, 12H), 2.26 (t, J = 7.3 Hz, 2H), 1.83 (m, 
8H), 1.65 (dq, J = 22.2, 7.6 Hz, 5H), 1.41 (p, J = 8.2 Hz, 2H), 0.85 (s, 1H), 0.65 (s, 
3H), 0.58 (s, 3H). 13C-NMR (126 MHz, CD3OD) δ 176.5, 169.7, 168.2, 165.1, 164.0, 
162.3, 162.0, 152.8, 151.5, 146.1, 139.7, 133.2, 130.3, 128.8, 127.1, 126.4, 123.5, 
120.5, 120.4, 114.9, 113.8, 95.7, 68.9, 66.1, 56.2, 54.8, 41.00, 40.8, 39.4, 36.7, 30.0, 
27.4, 26.4, 24.0, -0.3, -1.9. HRMS (ES) calculated for C72H82N11O9Si+([M+H]+) m/z: 
1272.6066, found 1272.6047.  
The solid was dissolved in 50.6 μL of DMSO (10 mM solution) and kept in the freezer 


































SiR-C4-COOH (74 μL, 13.5 mM, 1 equiv.), DIEA (5 μL, 30 eq), TSTU (12 μL, 100 mM, 
1.1 eq) and Py-PDS (25 μL, 50 mM, 1.1 eq) were left react together for 4 hours 
following the general method described above. The final compound was dried to afford 
the TFA salt of the title compound as an intense blue powder (SiR-C4-
PyPDS×2CF3CO2H, 1.06 mg, 0.72 μmol, 72%). 1H-NMR (500 MHz, CD3OD) δ 8.43 
(dd, J = 8.4, 0.8 Hz, 2H), 8.27 – 8.18 (m, 3H), 8.14 – 8.05 (m, 5H), 7.94 (ddd, J = 8.4, 
7.0, 1.5 Hz, 2H), 7.81 (d, J = 1.6 Hz, 1H), 7.69 (ddd, J = 8.2, 6.9, 1.1 Hz, 2H), 7.23 (d, 
J = 2.9 Hz, 2H), 6.93 (d, J = 9.4 Hz, 2H), 6.70 (dd, J = 9.5, 2.9 Hz, 2H), 4.33 (t, J = 5.3 
Hz, 2H), 4.04 – 3.95 (m, 4H), 3.65 (t, J = 5.3 Hz, 2H), 3.45 (t, J = 6.9 Hz, 2H), 3.20 (s, 
12H), 2.36 (t, J = 7.0 Hz, 2H), 2.20 (s, 8H), 1.95 (p, J = 6.9 Hz, 2H), 0.66 (s, 3H), 0.55 
(s, 3H). 13C-NMR (126 MHz, CD3OD) δ 176.0 , 169.8, 168.1, 165.7, 164.2, 161.7, 
161.5, 152.7, 151.3, 144.9, 133.6, 129.0, 127.4, 125.6, 123.7, 120.7, 120.3, 115.0, 
114.0, 95.7, 69.1, 66.4, 56.2, 54.7, 40.8, 39.7, 34.3, 31.7, 29.1, 26.0, 24.0, 22.4, 13.3, 
-0.4, -1.9. HRMS (ES) calculated for C70H78N11O9Si+ ([M+H]+) m/z: 1244.5753, found 
1244.5739.  
The solid was dissolved in 71.9 μL of DMSO (10 mM solution) and kept in the freezer 







































SiR-C8-COOH (50 μL, 18 mM, 1 equiv.), DIEA (8 μL, 50 eq), TSTU (11 μL, 100 mM, 
1.2 eq) and Py-PDS (27 μL, 50 mM, 1.5 eq) were left react together for 18 hours 
following the general method above. The final compound was dried to afford the TFA 
salt of the title compound as an intense blue powder (SiR-C8-PyPDS×2CF3CO2H, 0.99 
mg, 0.65 μmol, 72%). 1H-NMR (500 MHz, CD3OD) δ 8.40 (dd, J = 8.3, 0.8 Hz, 2H), 
8.23 – 8.17 (m, 3H), 8.08 (s, 2H), 8.06 – 8.01 (m, 3H), 7.91 (ddd, J = 8.4, 6.9, 1.4 Hz, 
2H), 7.80 (d, J = 1.7 Hz, 1H), 7.66 (ddd, J = 8.2, 6.9, 1.1 Hz, 2H), 7.20 (d, J = 2.8 Hz, 
2H), 6.89 (d, J = 9.5 Hz, 2H), 6.66 (dd, J = 9.5, 2.9 Hz, 2H), 4.38 (t, J = 5.3 Hz, 2H), 
4.00 – 3.94 (m, 4H), 3.69 (t, J = 5.3 Hz, 2H), 3.38 (t, J = 7.0 Hz, 2H), 3.20 (s, 12H), 
2.37 – 2.03 (m, 10H), 1.44 – 1.20 (m, 10H), 0.69 (s, 3H), 0.52 (s, 3H). 13C-NMR (126 
MHz, CD3OD) δ 176.7, 169.7, 168.2, 165.3, 164.0, 161.7, 161.4, 154.4, 152.7, 151.4, 
145.8, 133.3, 128.8, 127.2, 126.2, 123.6, 120.9, 120.3, 114.9, 113.8, 95.6, 69.0, 66.2, 
56.2, 54.8, 41.2, 40.8, 39.4, 36.9, 31.8, 31.7, 31.5, 30.3, 30.1, 30.0, 29.4, 29.3, 29.1, 
29.0, 28.8, 27.9, 26.8, 24.0, 22.7, 22.6, 22.4, 22.3, 22.1, 13.6, 13.4, 13.3, 13.1, 13.0, 
-0.4, -1.9. HRMS (ES) calculated for C74H86N11O9Si+ ([M+H]+) m/z: 1300.6379, found 
1300.6338.  
The solid was dissolved in 64.7 μL of DMSO (10 mM solution) and kept in the freezer 




































Oligonucleotides used  
All oligonucleotides were HPLC purified and used as supplied. Stock solutions of 100 
µM were prepared in MiliQ purified water. Unless otherwise stated all fluorescence, 
measurements were taken at 20 °C on a Varian Cary Eclipse Fluorescence 
Spectrometer fitted with a Varian temperature control unit. The sequences used for 
the various experiments described in the manuscript are reported in Table 1. 
 
Name Supplier  Sequence (5’ to 3’) 
FRET H-telo Biomers  FAM-GGGTTAGGGTTAGGGTTAGGG-TAMRA 
FRET c-Kit1 Biomers  FAM-GGG AGG GCG CTG GGA GGA GGG-TAMRA 
H-telo complementary  Sigma  CCC TAA CCC TAA CCC TAA CCC 
c-Kit1 complementary  Sigma  CCC TCC TCC CAG CGC CCT CCC 
FRET2 H-telo IDT  Cy5-AGGGTTAGGGTTAGGGTTAGGGAGAGGTAAAAG GATAATGG CCACGGTGCGGACGGC-Biotin 
FRET2 Myc IDT  Cy5-TGGGTGGGTAGGGTGGGAGAGGTAAAAGGATAAT GGCCACGGTGCGGACGGC-Biotin 
FRET2 c-Kit1 IDT  Cy5-AGGGAGGGCGCTGGGAGGAGGGAGAGGTAAAAG GATAATGGCCACGGTGCGGACGGC-Biotin 
FRET2 comp IDT  GCCGTCCGCACCGTGGCCATTATCCTTT-Cy3-TACCTCT 
c-Kit1 Sigma  AGG GAG GGC GCT GGG AGG AGG G 
Myc Sigma  TGG GTG GGT AGG GTG GGT AA 
h-Telo Invitrogen  A GGG TTA GGG TTA GGG TTA GGG T 
dsDNA Invitrogen  CAA TCG GAT CGA ATT CGA TCC GAT TG 
MYC-mut Invitrogen  T TGA GTG TGT GTA GTG TGT GTA AA 
MYC for sm-binding Invitrogen  Biotin-TGA GGG TGG GTA GGG TGG GTA A-3¢-Alexa488  
MYC-mut for sm-binding Invitrogen  Biotin-TGA GTG TGT GTA GTG TGT GTA A-3¢-Alexa488  
 
Table 1: Oligonucleotide sequences used in this study. 
  
All oligonucleotides were HPLC purified and used as supplied. Stock solutions of 100 
µM were prepared in MiliQ purified water. Unless otherwise stated all fluorescence 
measurements were taken at 20 °C on a Varian Cary Eclipse Fluorescence 




SiR-PDS and SiR-iPDS were stocked at 10mM concentration, dissolved in DMSO 
(Thermofisher Scientific, cat# 20688).  U2OS in a density of 40,000 cells/ml were 
seeded one night before they were treated with serial dilutions of SiR-PDS and SiR-
iPDS (the maximum concentration for both drugs were 50µM) for 24 h. Cell viability 
was then determined via a CellTitre-Glo One Solution assay (Promega, cat # G8461) 
according to manufacturer’s protocol. Each serial dilution has 4 replications. Curves 
were plotted averaging the 4 replicates in Prism (GraphPad v6) using a non-linear 
regression model, “dose-response – inhibition” equation [log(inhibitor) vs. normalised 







Supplementary Figure 1: Optimization of the linker length between PyPDS and 
SiR.  Fluorescence light-up measurements obtained with 100 nM solutions of SiR-C4-
PyPDS, SiR-C6-PyPDS and SiR-C8-PyPDS in the presence of different 
oligonucleotides (10 mM), as described in the methods section: “SiR-PyPDS 
analogues G4-binding comparison”. Varying the linker length between SiR and the 
PyPDS scaffold revealed that the highest fluorescence light-up response was 
observed for the C6 linker in the presence of G4-folding oligonucleotides. The data 
are plotted as the ratio of the fluorescence intensity emission of each SiR-compound 
(100 nM) measured at 633 nm in the presence of 10 mM G4-oligos (c-Myc, hTelo and 
c-kit1), over the fluorescent emission measured at 633 nm for the same SiR-analogue 
(100 nM) in buffer only. Data are plotted as the average of 4 independent replicates. 


































Supplementary Figure 2: SiR-PyPDS fluorescence light-up response upon G4-
binding. Fluorescence titration of SiR-PyPDS in presence of different 
oligonucleotides, as described in the methods section: “Fluorescence titrations”. SiR-
PyPDS displayed a selective light-up response upon titration with G4-folding 
oligonucleotides, whereas negligible fluorescence increase was measured upon 
titration with ssDNA and dsDNA. Data are plotted as the ratio of the SiR fluorescence 
emission at 633 nm for every titration point over the emission measured in buffer alone 
and normalised to the highest fluorescence emission measured (100%). The data are 
plotted as an average of 3 independent replicates. Error bars indicate mean ± sd.  
SiR-PyPDS measured apparent Kd are: MYC 0.63 ± 0.08 µM; Kit-1 1.0 ± 0.1 µM; h-

























Supplementary Figure 3: Differential G4-binding of SiR-PyPDS and SiR-iPyPDS. 
Fluorescence titrations obtained exciting at 633nm a solution of either SiR-PyPDS or 
SiR-iPyPDS in the presence of increasing concentrations of a G4-folded 
oligonucleotide (MYC), as described in the methods section: “Fluorescence titrations”. 
SiR-PyPDS displayed a selective light-up response upon G4-binding whereas SiR-
iPyPDS showed negligible fluorescence emission variation upon titration with either 
oligonucleotide. Data are plotted as average of 3 independent replicates and using the 





Supplementary Figure 4: Circular Dichroism analysis of MYC oligonucleotides 
used for in vitro experiments:  CD spectra trace confirming folded state of the G4-
MYC oligonucleotide used for surface binding experiments and unfolded state of the 
mutant version MYC-mut both used at 10 µM concentration and annealed in 100 mM 
K+ buffer pH = 7.4. This experiment has been repeated 3 times with consistent 
outcomes. 
 










































Figure 5: Binding of SiR-PyPDS to different quadruplexes in vitro. The number of 
binding events observed for SiR-PyPDS and SiR-iPyPDS binding to G4s in vitro varies 
for different G4 sequences (250 pM concentration of both probes in all cases except 
for MYC where it was 25 pM). Error bars indicate mean ± sd. n = 6 measurements for 





Figure 6: Growth inhibition curves obtained with SiR-PyPDS (left) and SiR-
iPyPDS (right) in U2OS cells. Growth inhibition studies indicate that no significant 
cellular toxicity is elicited by treatment of either SiR-PyPDS or Sir-iPyPDS over a 24 h 
treatment for doses up to 10 µM. Error bars indicate mean ± sd. n = 4 measurements 
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